The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Open accessAbstract
SUMMARY Small cell lung cancer is initially highly responsive to cisplatin and etoposide but in almost every case becomes rapidly chemoresistant, leading to death within one year. We modeled acquired chemoresistance in vivo using a series of patient-derived xenografts to generate paired chemosensitive and chemoresistant cancers. Multiple chemoresistant models demonstrated suppression of SLFN11, a factor implicated in DNA damage repair deficiency. In vivo silencing of SLFN11 was associated with marked deposition of H3K27me3, a histone modification placed by EZH2, within the gene body of SLFN11, inducing local chromatin condensation and gene silencing. Inclusion of an EZH2 inhibitor with standard cytotoxic therapies prevented emergence of acquired resistance and augmented chemotherapeutic efficacy in both chemosensitive and chemoresistant models of small cell lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Self-citationZheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,513
Architecture of the human regulatory network derived from ENCODE data
Gerstein, M. B., Kundaje, A., Hariharan, M., Landt, S. G., Yan, K.-K., Cheng, C., Mu, X. J., Khurana, E., Rozowsky, J., Alexander, R., et al. (2012) · Nature · doi:10.1038/nature11245 · Cited by 1,442
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S., & Swanton, C. (2016) · Genome Biology · doi:10.1186/s13059-016-0893-4 · Cited by 1,216
Rudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z., Shames, D. S., Bergbower, E. A., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,077
Self-citation(1986) · Lung Cancer · doi:10.1016/s0169-5002(86)80023-x · Cited by 900
Pott, S., & Lieb, J. D. (2015) · Nature Genetics · doi:10.1038/ng.3167 · Cited by 761
De Smet, C., Lurquin, C., Lethé, B., Martelange, V., & Boon, T. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7327 · Cited by 598
Shepherd, F. A., Crowley, J., Van Houtte, P., Postmus, P. E., Carney, D., Chansky, K., Shaikh, Z., & Goldstraw, P. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815bdc0d · Cited by 548
Daniel, V. C., Marchionni, L., Hierman, J. S., Rhodes, J. T., Devereux, W. L., Rudin, C. M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4210 · Cited by 467
Self-citationTargeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 439
Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0011 · Cited by 436
Self-citationLoss of BAP1 function leads to EZH2-dependent transformation
LaFave, L. M., Béguelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A., Papalexi, E., Keller, M. D., Hricik, T., Konstantinoff, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3947 · Cited by 381
Self-citationPutative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
Zoppoli, G., Regairaz, M., Leo, E., Reinhold, W. C., Varma, S., Ballestrero, A., Doroshow, J. H., & Pommier, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205943109 · Cited by 369
Lok, B. H., Gardner, E. E., Schneeberger, V. E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B. A., Riaz, N., Powell, S. N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1040 · Cited by 344
Self-citationWang, J., Zhuang, J., Iyer, S., Lin, X.-Y., Greven, M. C., Kim, B.-H., Moore, J., Pierce, B. G., Dong, X., Virgil, D., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1221 · Cited by 279
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
Fillmore, C. M., Xu, C., Desai, P. T., Berry, J. M., Rowbotham, S. P., Lin, Y.-J., Zhang, H., Marquez, V. E., Hammerman, P. S., Wong, K.-K., et al. (2015) · Nature · doi:10.1038/nature14122 · Cited by 255
Poirier, J. T., Gardner, E. E., Connis, N., Moreira, A. L., de Stanchina, E., Hann, C. L., & Rudin, C. M. (2015) · Oncogene · doi:10.1038/onc.2015.38 · Cited by 248
Self-citationA crucial requirement for Hedgehog signaling in small cell lung cancer
Park, K.-S., Martelotto, L. G., Peifer, M., Sos, M. L., Karnezis, A. N., Mahjoub, M. R., Bernard, K., Conklin, J. F., Szczepny, A., Yuan, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2473 · Cited by 247
Self-citationRAC1 activation mediates Twist1-induced cancer cell migration
Yang, W.-H., Lan, H.-Y., Huang, C.-H., Tai, S.-K., Tzeng, C.-H., Kao, S.-Y., Wu, K.-J., Hung, M.-C., & Yang, M.-H. (2012) · Nature Cell Biology · doi:10.1038/ncb2455 · Cited by 231
Different Levels of Twist1 Regulate Skin Tumor Initiation, Stemness, and Progression
Beck, B., Lapouge, G., Rorive, S., Drogat, B., Desaedelaere, K., Delafaille, S., Dubois, C., Salmon, I., Willekens, K., Marine, J.-C., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2014.12.002 · Cited by 203
Targeting the DNA Repair Pathway in Ewing Sarcoma
Stewart, E., Goshorn, R., Bradley, C., Griffiths, L. M., Benavente, C., Twarog, N. R., Miller, G. M., Caufield, W., Freeman, B. B., Bahrami, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.028 · Cited by 180
Sato, T., Kaneda, A., Tsuji, S., Isagawa, T., Yamamoto, S., Fujita, T., Yamanaka, R., Tanaka, Y., Nukiwa, T., Marquez, V. E., et al. (2013) · Scientific Reports · doi:10.1038/srep01911 · Cited by 178
Schmidt, J. M., Panzilius, E., Bartsch, H. S., Irmler, M., Beckers, J., Kari, V., Linnemann, J. R., Dragoi, D., Hirschi, B., Kloos, U. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.032 · Cited by 170
Nogales, V., Reinhold, W. C., Varma, S., Martinez-Cardus, A., Moutinho, C., Moran, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6413 · Cited by 169
Polley, E., Kunkel, M., Evans, D., Silvers, T., Delosh, R., Laudeman, J., Ogle, C., Reinhart, R., Selby, M., Connelly, J., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw122 · Cited by 169
SLFN11 inhibits checkpoint maintenance and homologous recombination repair
Mu, Y., Lou, J., Srivastava, M., Zhao, B., Feng, X., Liu, T., Chen, J., & Huang, J. (2016) · The EMBO Reports · doi:10.15252/embr.201540964 · Cited by 160
Acquired Tissue-Specific Promoter Bivalency Is a Basis for PRC2 Necessity in Adult Cells
Jadhav, U., Nalapareddy, K., Saxena, M., O’Neill, N. K., Pinello, L., Yuan, G.-C., Orkin, S. H., & Shivdasani, R. A. (2016) · Cell · doi:10.1016/j.cell.2016.04.031 · Cited by 139 · cited 1×
“A shift in global repressive histonemethylationmay have pleiotropic effects on gene expression that manifest in a cell-line-specific manner (Jadhav et al., 2016).”
Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients
Horita, N., Yamamoto, M., Sato, T., Tsukahara, T., Nagakura, H., Tashiro, K., Shibata, Y., Watanabe, H., Nagai, K., Inoue, M., et al. (2015) · Scientific Reports · doi:10.1038/srep15437 · Cited by 107
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
Tang, S.-W., Bilke, S., Cao, L., Murai, J., Sousa, F. G., Yamade, M., Rajapakse, V. N., Varma, S., Helman, L. J., Khan, J. I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2112 · Cited by 106
Sousa, F. G., Matuo, R., Tang, S.-W., Rajapakse, V. N., Luna, A., Sander, C., Varma, S., Simon, P. H. G., Doroshow, J. H., Reinhold, W. C., et al. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.01.011 · Cited by 61
Schneeberger, V. E., Allaj, V., Gardner, E. E., Poirier, J. T., & Rudin, C. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160587 · Cited by 59
Self-citationMaia, A. M., da Silva, J. H., Mencalha, A. L., Caffarena, E. R., & Abdelhay, E. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-184 · Cited by 29
(1950) · doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
Cited by
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Self-citationSmall-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.87 · Cited by 904
Epigenetics in health and disease
Zhang, L., Lu, Q., & Chang, C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3449-2_1 · Cited by 689
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4407 · Cited by 652
Self-citation
Metadata
- Authors
- Gardner, E. E., Lok, B. H., Schneeberger, V. E., Desmeules, P., Miles, L. A., Arnold, P. K., Ni, A., Khodos, I., de Stanchina, E., Nguyen, T., Sage, J., Campbell, J. E., Ribich, S., Rekhtman, N., Dowlati, A., Massion, P. P., Rudin, C. M., & Poirier, J. T.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 31
- Issue
- 2
- Pages
- 286-299
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2588648082
- Cited by
- 526
- References
- 44
- FWCI
- 18.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.